跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
布瑞亭 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Sugammadex Sodium Injection
Approved
化学药品
Sugammadex Sodium Injection
Merck Sharp & Dohme BV
🇨🇳 National Medical Products Administration
Approval Date
Oct 14, 2022
Approval ID
6c6357569afdfff2
Company
Merck Sharp & Dohme BV
Type
化学药品
Approval Details
Approval Id
6c6357569afdfff2
Approval Number
国药准字HJ20181176
Generic Name
舒更葡糖钠注射液
Generic Name En
Sugammadex Sodium Injection
Trade Name
布瑞亭
Drug Type
化学药品
Dosage Form
注射剂
Strength
按舒更葡糖钠活性实体与单-羟基舒更葡糖钠活性实体的总量计算 5ml:500mg
Reg Date
2022-10-14
Expired Date
2027-10-13
Company Name
Merck Sharp & Dohme BV
Production Company Name
Patheon Manufacturing Services LLC
Company Detail Path
/organization/merck-sharp-and-dohme-bv
Production Company Detail Path
/organization/patheon-manufacturing-services-llc
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Oct 14, 2022
Approval ID
6c6357569afdfff2
Type
化学药品
Back to NMPA Approvals